In what Regeneron CEO Len Schleifer called a “paradigm-shifting agreement,” Sanofi and Regeneron sealed a deal with the pharmacy benefit manager Express Scripts cutting the price of their cholesterol drug Praulent (alirocumab) by up to $10,000 a year in exchange for easier access for Express Scripts patients.
Source: Drug Industry Daily